We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Faulty Protein Interaction Disrupts Neuromuscular Junctions and Triggers ALS

By Gerald M. Slutzky, PhD
Posted on 01 Dec 2016
Humans and mice are protected from developing amyotrophic lateral sclerosis (ALS) by the action of muscle fibers that secrete and concentrate the fibroblast growth factor binding protein 1 (FGFBP1) at neuromuscular junctions.

The FGFBP1 gene encodes a secreted fibroblast growth factor carrier protein, which plays a critical role in cell proliferation, differentiation, and migration by binding to fibroblast growth factors and potentiating their biological effects on target cells.

ALS is a specific disorder that involves the death of neurons. More...
The disease, for which there is no cure, is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. Most ALS sufferers die from respiratory failure. The neuromuscular junction (NMJ) is critical for all voluntary movement. Its malformation during development and degeneration during aging or in ALS impairs motor function.

Investigators at the Virginia Tech Carilion Research Institute (Roanoke, VA, USA) reported in the November 14, 2016, online edition of The Journal of Neuroscience that while FGFBP1 expression increased during development, its expression decreased prior to NMJ degeneration during aging and in the SOD1G93A ALS mouse model. FGFBP1 expression was shown to be inhibited by increased accumulation of transforming growth factor-beta1 (TGF-beta1) in skeletal muscles and at their NMJs. When they examined the impact of deleting FGFBP1 on NMJs, the investigators found that in the absence of FGFBP1, NMJs exhibited structural abnormalities in developing and in middle age mice. Deletion of FGFBP1 from SOD1G93A mice also accelerated NMJ degeneration and death.

These findings suggested that targeting the interaction between FGFBP1 and TGF-beta1 signaling could hold promise for slowing age- and disease-related degeneration of NMJs.

"TGF-beta1 is upregulated in ALS and in turn blocks expression of FGFBP1, which is released by muscle fibers to preserve the integrity of the neuromuscular junction," said senior author Dr. Gregorio Valdez, assistant professor of biological sciences at the Virginia Tech Carilion Research Institute. "The body is trying to help itself by generating more TGF-beta1. Unfortunately, TGF-beta1 accumulates at the synapse where it blocks expression of FGFBP1, accelerating degeneration of the neuromuscular junction. Our findings suggest that targeting these molecules may allow these important synapses to stay in place, and slow the progression of ALS."

Related Links:
Virginia Tech Carilion Research Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Gold Member
Collection and Transport System
PurSafe Plus®
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.